Oral GLP-1 drugs are likely to expand the market massively The more disruptive development may actually be oral agents. Many patients are willing to take a pill but reluctant to self-inject indefinite
Eli Lilly licensed global rights, excluding South Korea, to Hanmi Pharm's investigational long-acting GLP-2 analogue sonefpeglutide across multiple indications, under a deal potentially worth around $
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly PUBLISHED TUE, MAR 31 20267:39 AM EDTUPDATED TUE, MAR 31 20262:10 PM EDT Annika Kim Cons
Comments